10-Q: Mirion Technologies Reports Q1 2025 Results: Revenue Up, Net Income Positive

Mirion Technologies saw revenue increase and net income turn positive in the first quarter of 2025, driven by growth in both its Medical and Nuclear & Safety segments.

Summary

• Mirion Technologies, Inc. reported its financial results for the first quarter of 2025.
• Revenues increased to $202.0 million, up from $192.6 million in the same period last year.
• The Medical segment contributed $68.6 million in revenue, while the Nuclear & Safety segment generated $133.4 million.
• The company achieved a net income of $0.4 million, a significant improvement from the net loss of $26.5 million in Q1 2024.
• The Medical segment reported income from operations of $6.7 million, and the Nuclear & Safety segment reported $21.7 million.
• Backlog remained relatively stable at $813.5 million as of March 31, 2025, compared to $811.9 million at the end of 2024.
• The company repurchased 1.2 million shares of its Class A common stock under a previously announced program.
• The company is managing risks associated with foreign currency fluctuations and interest rates through derivative instruments.

Sentiment

Score: 7

Explanation: The sentiment is positive due to increased revenue, a return to profitability, and active management of financial risks. However, concerns about geopolitical risks, inflation, and tax rates temper the overall outlook.

Positives

• Revenue increased by $9.4 million compared to the same quarter last year.
• Net income turned positive, indicating improved profitability.
• Both the Medical and Nuclear & Safety segments contributed to revenue growth.
• The company is actively managing financial risks through hedging strategies.
• The company has a substantial backlog, providing visibility into future revenue.
• The company is returning capital to shareholders through a share repurchase program.

Negatives

• The effective income tax rate was 33.3%, higher than the U.S. statutory rate of 21% due to permanent differences and valuation allowances.
• The company is exposed to risks related to geopolitical and trade conditions, including tariffs and sanctions.
• The company is exposed to risks related to inflation and interest rates.

Risks

• Geopolitical and trade conditions, including the relationship between the United States and China, and the conflict in the Middle East, could impact the company's operations.
• Inflation and rising interest rates could increase costs and debt service expenses.
• Tariffs and sanctions could increase costs and disrupt supply chains.
• The company faces risks related to government budgets and potential spending cuts.
• The company is exposed to foreign currency exchange rate fluctuations.
• The company is exposed to tax risks, including changes in tax rates and potential tax liabilities.

Future Outlook

Mirion management believes that net cash provided by operating activities, augmented by long-term debt arrangements, will provide adequate liquidity for the next 12 months of independent operations, as well as the resources necessary to invest for growth in existing businesses and manage its capital structure on a shortand long-term basis.

Management Comments

• Mirion management believes that net cash provided by operating activities, augmented by long-term debt arrangements, will provide adequate liquidity for the next 12 months of independent operations, as well as the resources necessary to invest for growth in existing businesses and manage its capital structure on a shortand long-term basis.

Industry Context

Mirion operates in the radiation detection and measurement market, serving the medical, nuclear, and defense industries, the company's performance is influenced by trends in these sectors, such as the growing demand for nuclear power as a clean energy source and the increasing adoption of advanced technologies in medical radiation therapy.

Comparison to Industry Standards

• It is difficult to compare Mirion directly to industry standards without detailed competitor data.
• However, companies like Fortive and Danaher, which operate in similar industrial technology spaces, often trade at EBITDA multiples of 15x-20x.
• Mirion's Q1 Adjusted EBITDA of $46.7 million annualizes to $186.8 million, suggesting a potential enterprise value in the range of $2.8 billion to $3.7 billion based on these multiples.
• This is a rough estimate and does not account for Mirion's specific growth prospects, debt levels, or other factors.

Management Changes

Legal Proceedings

• In April 2023, one of our Russian customers made a claim against the Company, including liquidated damages for certain delays under the terms of an active project, in the amount of $19.3 million, and sent an updated claim statement in October 2023 totaling $21 million ($18 million of which accrue daily penalties), subject to a $14 million contractual cap (all amounts converted from Euros to U.S. Dollars).
• In November 2024, the Company reached an agreement to modify the underlying contract and the claim was rescinded by the customer.
• In June 2023, the same Russian customer made a demand against the Company for the return of all payments received by the Company ($10.2 million) related to a Finland nuclear power plant project cancelled in May 2022.
• In September 2024, the Company entered into a settlement agreement with the customer agreeing to refund 4.4 million to the customer.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and the share repurchase program.
• Employees may be affected by changes in compensation costs and potential restructuring initiatives.
• Customers may experience changes in product pricing due to tariffs and supply chain disruptions.
• Suppliers may be affected by changes in sourcing strategies and trade restrictions.

Next Steps

• The company will continue to monitor the social, political, regulatory and economic environment in Ukraine and Russia, and will consider actions as appropriate.
• The Company will continue to monitor the social, political, regulatory and economic environment in Ukraine and Russia, and will consider actions as appropriate.

Key Dates

Keywords

revenue, net income, Mirion Technologies, Nuclear & Safety, Medical, financial results, Q1 2025, backlog, share repurchase, segment performance